Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AKBA logo AKBA
Upturn stock ratingUpturn stock rating
AKBA logo

Akebia Ther (AKBA)

Upturn stock ratingUpturn stock rating
$3.65
Last Close (24-hour delay)
Profit since last BUY50.21%
upturn advisory
Consider higher Upturn Star rating
BUY since 43 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: AKBA (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

4 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $7.25

Year Target Price $7.25

Analyst’s Price TargetsFor last 52 week
$7.25Target price
Low$0.91
Current$3.65
high$4.08

Analysis of Past Performance

Type Stock
Historic Profit 4.34%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 958.62M USD
Price to earnings Ratio -
1Y Target Price 7.4
Price to earnings Ratio -
1Y Target Price 7.4
Volume (30-day avg) -
Beta 0.84
52 Weeks Range 0.91 - 4.08
Updated Date 06/29/2025
52 Weeks Range 0.91 - 4.08
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.21

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -24.51%
Operating Margin (TTM) 23.85%

Management Effectiveness

Return on Assets (TTM) -4.26%
Return on Equity (TTM) -553.45%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 898081622
Price to Sales(TTM) 5.18
Enterprise Value 898081622
Price to Sales(TTM) 5.18
Enterprise Value to Revenue 4.86
Enterprise Value to EBITDA 136.34
Shares Outstanding 262636000
Shares Floating 257367361
Shares Outstanding 262636000
Shares Floating 257367361
Percent Insiders 3.59
Percent Institutions 38.87

Analyst Ratings

Rating 4.75
Target Price 7.25
Buy 1
Strong Buy 3
Buy 1
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Akebia Ther

stock logo

Company Overview

overview logo History and Background

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients with kidney disease. Founded in 2007, it has focused primarily on hypoxia-inducible factor (HIF) stabilizers.

business area logo Core Business Areas

  • Renal Disease Therapeutics: Akebia develops and seeks to commercialize treatments for anemia due to chronic kidney disease (CKD) and other kidney-related conditions.

leadership logo Leadership and Structure

Akebia is led by a board of directors and an executive team. The CEO is John P. Butler. The company has a typical corporate structure with departments focusing on R&D, clinical development, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Vafseo (vadadustat): Vafseo is an oral HIF prolyl hydroxylase (HIF-PH) inhibitor approved in the EU, UK, Switzerland, and other countries for the treatment of anemia associated with chronic kidney disease in adult patients on dialysis. The company received a Complete Response Letter (CRL) from the FDA in 2022. Major competitors include injectable erythropoiesis-stimulating agents (ESAs) and other potential oral HIF-PH inhibitors.

Market Dynamics

industry overview logo Industry Overview

The renal disease therapeutics market is substantial and growing, driven by the increasing prevalence of CKD worldwide. There is significant unmet need for effective and convenient treatments, particularly for anemia associated with CKD.

Positioning

Akebia is positioned as an innovator in the oral HIF-PH inhibitor space. Its competitive advantage lies in its vadadustat formulation and potential for improved patient convenience compared to injectable ESAs.

Total Addressable Market (TAM)

The global anemia associated with CKD market is estimated to be worth billions of dollars. Akebia aims to capture a significant share of this market with Vafseo and future product candidates.

Upturn SWOT Analysis

Strengths

  • Novel HIF-PH inhibitor technology
  • Established partnerships in key markets
  • Experienced management team
  • Approved product in multiple territories.

Weaknesses

  • FDA rejection of vadadustat
  • Reliance on partner revenue
  • Significant debt
  • Uncertainty regarding future regulatory approvals in the US.

Opportunities

  • Potential for US FDA approval with additional data or a new clinical trial
  • Expansion into new markets
  • Development of new indications for vadadustat or other HIF-PH inhibitors
  • Strategic partnerships or acquisitions.

Threats

  • Competition from existing ESAs and other emerging therapies
  • Unfavorable regulatory decisions
  • Pricing pressures
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • JNJ
  • FGEN

Competitive Landscape

Akebia competes with established pharmaceutical companies in the renal disease market. Its competitive advantage lies in its oral HIF-PH inhibitor technology, but it faces challenges related to regulatory approval and market access. Amgen and JNJ currently hold major market share for current treatments, mostly through ESAs, while FGEN is another competitor working with HIF-PH inhibitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by R&D spending and regulatory hurdles, leading to slow revenue growth.

Future Projections: Future growth is highly dependent on securing US FDA approval for vadadustat and expanding into new markets.

Recent Initiatives: Akebia is focused on pursuing strategic partnerships and streamlining operations to improve its financial position and regulatory approval.

Summary

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for kidney disease. While it faces challenges, Akebia has a novel oral HIF-PH inhibitor technology and strategic partnerships. Future success hinges on obtaining regulatory approval in the U.S., managing debt, and competing effectively. The complete response letter from the FDA, coupled with high debt, makes Akebia a high-risk investment. Akebia needs to secure US approval to demonstrate a viable product offering.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Investor presentations
  • Analyst reports
  • Press releases

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change without notice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Akebia Ther

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2014-03-20
CEO, President & Director Mr. John P. Butler MBA
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 181
Full time employees 181

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.